# A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

> **NCT05917288** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Belimumab
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05917288
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-07
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917288, "A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05917288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*